Abcam, ab217377, Anti-Cytochrome P450 1A2 antibody

Size: 100µL
Rabbit Polyclonal Cytochrome P450 1A2 antibody. Suitable for IHC-P and reacts with Rat samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human CYP1A2 aa 200-300 conjugated to Keyhole Limpet Haemocyanin.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Rat,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human CYP1A2 aa 200-300 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.P05177

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Proclin 300Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cytochrome P450 1A2 often known as CYP1A2 is an important enzyme in the cytochrome P450 superfamily with a known mass around 58 kDa. It is mainly expressed in the liver where it functions in the metabolism of drugs and the bioactivation of various compounds. CYP1A2 also participates in the oxidation of small organic molecules which include xenobiotics and endogenous substrates. Due to its function researchers frequently study CYP1A2 substrates and its inhibitors to understand better its role in drug metabolism and toxicity.
Biological function summary
CYP1A2 plays a central role in the oxidative biotransformation of drugs and procarcinogens. It does not form part of a larger complex but interacts dynamically with other enzymes in the detoxification process. CYP1A2 metabolizes several clinical drugs such as caffeine and theophylline and regulates the detoxification of aromatic amines and hydrocarbons. Studying CYP1A2 inhibitors can provide insights into clinically relevant drug interactions and potential side effects in pharmacotherapy.
Pathways
CYP1A2 functions within the drug metabolism and synthesis of cholesterol steroids and other lipids pathways. In the drug metabolism pathway CYP1A2 works alongside other cytochrome P450 enzymes such as CYP1A1 and CYP1B1 which together ensure the metabolism and clearance of various exogenous and endogenous compounds. These pathways are vital for maintaining drug efficacy and preventing toxicity through the metabolic clearance of pharmaceutical agents and harmful substances.
CYP1A2 activity links to liver disorders and certain cancers. Altered enzyme activity may lead to hepatotoxicity a condition that arises from excessive accumulation of active drug metabolites in the liver. Furthermore due to its role in activating procarcinogens increased CYP1A2 activity relates to a higher risk of developing certain cancers including liver cancer. Researchers often explore these connections to better understand the enzyme's role in disease pathogenesis and to develop CYP1A2-directed therapies.